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http://dx.doi.org/10The MOZ-TIF2 translocation, which fuses monocytic leukemia zinc finger protein (MOZ) his-
tone acetyltransferase (HAT) with the nuclear co-activator TIF2, is associated with the devel-
opment of acute myeloid leukemia. We recently found that in the absence of MOZ HAT
activity, p16INK4a transcriptional levels are significantly increased, triggering an early
entrance into replicative senescence. Because oncogenic fusion proteins must bypass cellular
safeguard mechanisms, such as senescence and apoptosis, to induce leukemia, we hypothesized
that this repressive activity of MOZ over p16INK4a transcription could be preserved, or even
reinforced, in MOZ leukemogenic fusion proteins, such as MOZ-TIF2. We describe here that,
indeed, MOZ-TIF2 silences expression of the CDKN2A locus (p16INK4a and p19ARF), inhibits
the triggering of senescence and enhances proliferation, providing conditions favorable to
the development of leukemia. Furthermore, we describe that abolishing the MOZ HAT activ-
ity of the fusion protein leads to a significant increase in expression of the CDKN2A locus and
the number of hematopoietic progenitors undergoing senescence. Finally, we report that inhi-
bition of senescence by MOZ-TIF2 is associated with increased apoptosis, suggesting a role for
the fusion protein in p53 apoptosis-versus-senescence balance. Our results underscore the
importance of the HAT activity of MOZ, preserved in the fusion protein, for repression of
the CDKN2A locus transcription and the subsequent block of senescence, a necessary step
for the survival of leukemic cells. Copyright  2016 ISEH - International Society for Exper-
imental Hematology. Published by Elsevier Inc. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).The monocytic leukemia zinc finger protein (MOZ,
MYST3, KAT6A) is the founding member of the MYST
family of histone acetyltransferases (HATs) [1–3]. MOZ
is essential for hematopoietic stem cell (HSC) emergence
and self-renewal [4–6]. The gene encoding MOZ was
initially identified in several recurrent chromosomal trans-
locations, with either CBP, p300, or TIF2/NCOA2 found
in a distinct subtype of acute myeloid leukemia (AML)
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.1016/j.exphem.2015.12.006terized by a poor prognosis [2,7–10]. Remarkably, the
HAT domain of MOZ is preserved in the fusion protein,
and all the fusion partners of MOZ are themselves directly
(CBP, P300) or indirectly (TIF2 can interact with CBP via
the CBP interaction domain or CID [11]) involved in post-
translational histone modifications and transcriptional regu-
lation. This observation led to the proposition that abnormal
histone acetylation driven by the fusion proteins might be at
the origin of the leukemic transformation [12,13]. Alterna-
tively, it has been proposed that the ability of MOZ-TIF2 to
deplete CBP, particularly from the promyelocytic leukemia
(PML) bodies, results in subversion of normal gene expres-
sion leading to development of leukemia [14–16].
MOZ-TIF2 is able to immortalize murine hematopoietic
progenitors in vitro and to recapitulate AML in vivo in mu-
rine and zebrafish models [13,17–19]. Previous reports have
indicated that a functional CID or MOZ HAT activity is
required to increase the proliferative potential of hemato-
poietic progenitors in vitro, and to induce AML in vivo
[13,17,20].atology. Published by Elsevier Inc. This is an open access article under the
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Figure 1. (A) Flow cytometry profile of untransduced MEFs (UT) and MEFs transduced with the different lentiviruses (EF1GFP, 2AGFP_MOZTIF2, and
S8MOZ-TIF2) and therefore expressing GFP. Numbers represent the percentages of cells positive for GFP 48 hours after transduction in each case (n5 3 for
each genotype). Multiplicity of infection (MOI) 5 30. (B) PCR for the MOZ-TIF2 transcript on untransduced cells and MEFs transduced with the different
lentiviruses. (C) Quantitative PCR revealing the relative expression levels of p16INK4a/p19ARF in WT andMozHAT–/– MEFs (passage 3) untransduced or trans-
duced with the different lentiviruses. The transcript levels were normalized to b-actin for all reactions. Values reflect averages of triplicate samples. Bars
represent standard errors of the mean values. (D) Growth curves of cultures of WT and MozHAT–/– MEFs transduced with the different lentiviruses. The graph
represents the average values from three independent cultures. Passage numbers are indicated. Bars represent standard errors of the mean values.
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need to evade defense mechanisms, such as senescence
and apoptosis, to survive and proliferate. In this context,
MOZ has been found to regulate, upon cellular stress,
expression of the tumor suppressor gene p21 and to in-
crease premature senescence through acetylation of P53
[21,22]. In contrast to this positive role of MOZ in
inducing senescence, we, and others, have reported that
in the absence of MOZ, mouse embryonic fibroblasts
(MEFs) undergo an early entrance into replicative senes-
cence mediated by the upregulation of expression from
the CDKN2A locus (p16INK4a and p19ARF) [23,24]. These
observations raise the possibility that this repressive activ-
ity could be exacerbated in MOZ leukemic fusion pro-
teins. In this work, we sought to investigate thispossibility by determining the effect of MOZ-TIF2 expres-
sion on the transcriptional levels of p16INK4a/p19ARF and
proliferation of the targeted cells. We also investigated
the relevance of the HAT activity of MOZ, preserved in
all known leukemic proteins originated by MOZ translo-
cation, in this context.Methods
Purification of cKitþ cells
Bone marrow cells were stained with a biotinylated anti-cKit anti-
body (BD Biosciences, clone 2B8m 553353) and incubated with
the anti-biotin magnetic MACS beads (Miltenyi Biotec). cKitþ
cells were enriched using an LS column and a MACS Separator




Figure 1. (continued) (E) Flow cytometry profile of untransduced (UT) CD34þcKitþ hematopoietic progenitors and the same cells transduced with either
EF1GFP or 2AGFP_MOZTIF2 lentivirus. Numbers represent the percentages of cells positive for GFP 48 hours after transduction in each case. MOI 5 50.
(F) Specific PCR for the detection of MOZ-TIF2 transcripts in transduced CD34þcKitþ cells. (G) Growth curves of WT CD34þcKitþ cultures transduced
with the different lentiviruses. The graph represents the average values from three independent cultures. Passage numbers are indicated. Bars indicate stan-




Figure 2. (A) Schematic representation of the experimental design. Bone marrow cKitþ cells infected with a retrovirus encoding MOZ-TIF2 were tested for
their leukemic potential and senescence status. (B) Serial replating of MOZ-TIF2 (MT2)-expressing cells and GFP control cells (n 5 3). (C) Photographs of
the colonies after the second replating. Representative images from three independent experiments. (D) MGG staining of cytospin from the second replating.
Representative images from three independent experiments. (E) Analysis of HOXA9 transcript levels in cKitþ expressing MOZ-TIF2 or the control virus
(n 5 3). (F) Flow cytometry detection of MOZ-TIF2-expressing cells (GFPþ) in the bone marrow (BM) and the spleen of mice culled because of sickness.
Representative FACS plots of five mice. (G) Analysis of p16INK4a/p19ARF transcript levels in cKitþ expressing MOZ-TIF2 or cells transduced with the control
virus (n 5 3).
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Figure 2. (continued) (H) Western blot analysis for p16INK4a protein levels in the MOZ-TIF2 and control cells. Results are representative of two independent
experiments. (I) Flow cytometry analysis of cell cycle. (J) Photographs of MT2 and control cells after SA-b-Gal staining and quantification (n 5 3). (K)
Analysis of IL6 transcript levels in cKitþ expressing MOZ-TIF2 or in control cells (n 5 3).
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Embryoid bodies (EBs), generated as previously described [25],
or MEFs were trypsinized (TryplE, Gibco). Stained single-cell
suspensions were analyzed on a FACScan or a FACS Calibur
flow cytometer (Becton Dickinson) or sorted on a FACS Vantage
cell sorter (Becton Dickinson). Cell cycle analysis was per-
formed using the Click-iT EdU Alexa Fluor 647 Flow Cytometry
Assay Kit (Thermo Fisher Scientific). Apoptosis analysis was
performed using the PE Annexin V Apoptosis Detection Kit
(BD Biosciences).
Senescence-associated bgalactosidase staining
Senescence-associated b-galactosidase (SA-b-Gal) activity was
detected using the Senescence b-galactosidase Staining Kit from
Cell Signalling.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) was performed using the
High Cells Chip Kit (Diagenode) following the instructions of
the manufacturer.
Additional information concerning other techniques and mate-
rials can be found in the Supplementary Methods (online only,
available at www.exphem.org) [26–29].Results and discussion
To assess the effect of MOZ-TIF2 oncoprotein on the tran-
scriptional levels of the CDKN2A locus (p16INK4a/p19ARF),
we first transduced either wild-type (WT) or MOZHAT–/–
MEFs with two vectors linking MOZ-TIF2 to GFP eitherthrough a small S8 IRES or through a self-cleaving 2A pep-
tide sequence (Supplementary Figure E1, online only, avail-
able at www.exphem.org). Untransduced cells, as well as
cells transduced with a lentivirus expressing only GFP
(EF1GFP), were used as controls (Fig. 1A). Polymerase
chain reactions (PCRs) confirmed the presence of MOZ-
TIF2 transcripts in the transduced cells (Fig. 1B). A signif-
icant reduction in p16INK4a/p19ARF mRNA levels was
observed not only in WT MEFs, but also in MOZHAT–/–
MEFs, which, as previously reported [23], express higher
levels of p16INK4a/p19ARF than the WT cells (Fig. 1C). As
the GFP-2A-MOZ-TIF2 lentivirus (2AMT2) had higher
transduction efficiency (Fig. 1A), we chose this virus to
perform the subsequent experiments.
We next analyzed whether the lower levels of the
CDKN2A locus transcription were correlated with changes
in proliferation upon successive passages. As expected, the
MOZHAT–/– MEFs proliferated less than the WT MEFs. This
difference was maintained following transduction with
EF1GFP viruses (Fig. 1D). In contrast, expression of
MOZ-TIF2 conferred a clear growth advantage to both
WT and MOZHAT–/– MEFs (Fig. 1D). These results suggest
that overexpression of the MOZ-TIF2 fusion protein is able
to counteract the effect of the native MOZ protein and its
HAT deficient version.
To test whether the effect of MOZ-TIF2 expression was
also observed in hematopoietic progenitors, we transduced
WT CD34þcKitþ cells isolated from day 6 in vitro
235A. Largeot et al./ Experimental Hematology 2016;44:231–237differentiated embryonic stem cells with the 2AMT2 lenti-
virus (Fig. 1E). PCRs on sorted GFPþ cells confirmed the
presence of MOZ-TIF2 transcripts in these cells (Fig. 1F).
Similarly to MEFs, CD34þcKitþ hematopoietic progeni-
tors transduced with MOZ-TIF2 had an increased prolifer-
ation rate compared with the control cells (Fig. 1G).
We then studied the effect of MOZ-TIF2 on senescence
in leukemic cells transformed with this fusion protein.
cKitþ cells isolated from adult WT mouse bone marrow
were transduced with MOZ-TIF2 and control retrovirusesA
C
D
Figure 3. (A) Analysis of p16INK4a/p19ARF transcript levels in cKitþ cells express
control virus (n 5 2). (B) Western blot analysis of p16INK4a protein levels in the c
TIF2 cells. (C) Photographs of cells expressing either the WT or the mutant MO
quantification (right) (n 5 3). (D) ChIP analysis of the recruitment of the Ty1-ta
transcript levels in cKitþ expressing MOZ-TIF2 or the control virus (n 5 3).(Fig. 2A). As previously described [17,20], cells transduced
with MOZ-TIF2, but not with the GFP control viruses,
could be serially replated in vitro in methylcellulose cul-
tures (Fig. 2B), presented a blast morphology (Fig. 2C,
D), and expressed high levels of the homeotic gene
HoxA9 (Fig. 2E). Furthermore, these cells, when injected
into sublethally irradiated recipients, induced the develop-
ment of fully penetrant leukemia with concomitant invasion
of hematopoietic organs with GFPþ (MOZ-TIF2-
expressing) cells (Fig. 2F). This leukemic transformationB
E
ing MOZ-TIF2, MOZ-TIF2 with the mutated HAT domain of MOZ, or the
ells expressing the mutated form of MOZ-TIF2 compared with WT MOZ-
Z-TIF2 fusion protein and control cells after SA-b-Gal staining (left) and












Figure 3. (continued) (F) Western blot analysis of p53 and p53 acetylated at lysine 120 (p53K120) protein levels in cells expressing MOZ-TIF2 or control
cells. (G) Analysis of p21 transcript levels in cKitþ expressing MOZ-TIF2 or the control virus (n 5 3). (H) Flow cytometry analysis of apoptosis using
annexin V and 7ADD staining. Results are representative images from two independent experiments.
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expression of both genes encoded in the CDKN2A locus,
p16INK4a and p19ARF (Fig. 2G), a decrease in p16INK4a pro-
tein level (Fig. 2H), and a marked increase in cell division
(Fig. 2I). Accordingly, only a low percentage of cells ex-
pressing the MOZ-TIF2 fusion protein were positive for
SA-b-Gal (Fig. 2J), in contrast to control GFPþ cells. In
agreement with these results, cells transduced with the
MOZ-TIF2 fusion protein also expressed much lower levels
of interleukin (IL)-6, a member of the senescence-
associated secretory pathway (Fig. 2K), compared with
the cells transduced with the control vector. Together, these
results clearly indicate that expression of the MOZ-TIF2
fusion protein, though inducing the development of leuke-
mia, inhibits the triggering of senescence.
To determine the relevance of MOZ HAT activity, we
then transduced cells with a mutated version of MOZ-TIF2
(Q654E/G657E) that abrogates this activity [20]. We de-
tected dramatically higher expression levels of p16Ink4a/
p19ARF mRNA, p16Ink4 protein, and SA-b-Gal in these cells
than in cells transduced with MOZ-TIF2-expressing viruses
(Fig. 3A–C). These results suggest that the HAT activity of
MOZ is crucial to avoid replicative senescence.
We next wanted to check if the repression of p16INKa was
a direct effect of the binding of the MOZ-TIF2 fusion protein
to the p16INKa promoter. We therefore performed chromatin
immunoprecipitation (ChIP) analysis using a Ty1-tagged
MOZ-TIF2. Although we detected good enrichment of the
fusion protein at the HOXA9 promoter (a known target of
MOZ or MOZ-TIF2) [20,30], compared with the two nega-
tive controls (condensed region in chromosome 2 or pro-
moter of the TBP gene), we did not detect clear
enrichment of MOZ-TIF2 recruitment into the p16Ink4a pro-
moter (Fig. 3D). These data suggest that MOZ-TIF2 is re-
pressing p16INKa expression in an indirect manner.
In addition to its role in inhibition of senescence
through the CDKN2A locus, MOZ has been reported to
acetylate p53 to activate p21-dependent senescence after
DNA damage [21,22]. We therefore investigated the status
of this pathway in MOZ-TIF2 leukemic cells and detectedan increase in the transcriptional levels of p53 (Fig. 3E) in
these cells. Furthermore expression of MOZ-TIF2 was
associated with K120 acetylation of p53, whereas no acet-
ylated p53 was detected in cells expressing the control
vector or the mutated MOZ-TIF2 (Fig. 3F). Surprisingly,
p21 transcription levels were however reduced, and not
increased, upon expression of the MOZ-TIF2 fusion pro-
tein (Fig. 3G). Although this is consistent with the
decrease in the number of cells undergoing replicative
senescence, it does not reflect the previously described
positive effect of K120 acetylation of p53 on p21 expres-
sion [21,22,31,32]. Furthermore we detected a striking in-
crease in cells undergoing apoptosis in MOZ-TIF2
leukemic cells compared to cells transduced with the con-
trol virus (Fig. 3H). Together our results suggest that
MOZ-TIF2 alters the p53 apoptosis-versus-senescence
balance in favor of apoptosis. The exact molecular regula-
tion of this balance, and in particular the role of acetyla-
tion of p53 on lysine K120 in this process, is not yet
fully understood. Indeed, although p53 K120 acetylation
and p53-dependent p21 transcription are prevented by
deletion of MOZ or TIP60, suggesting a direct correlation
between these events [21,22,33], mutation of K120 of p53
results in a decrease in the capacity of p53 to activate
apoptosis, but has, in contrast, no effect on p21 transcrip-
tion [31,32].
We conclude from this work that the expression of
MOZ-TIF2 fusion protein represses the transcription of
p16INK4a and p19ARF and blocks senescence, and that the
MOZ HAT activity of the fusion protein is crucial for this
repressive activity. We propose that silencing of the
CDKN2A locus by MOZ fusion proteins could be an impor-
tant step in the expansion of cells harboring these onco-
genic mutations. Moreover, MOZ-TIF2 seems to be
acting on p53 apoptosis-versus-senescence balance. Finally,
as p16INK4a expression is a frequent target gene inactivated
in human cancers, our work also raises the prospect that tar-
geting the epigenetic HAT activity of MOZ [34] could
represent an interesting strategy to induce senescence and
eliminate oncogenic cells.
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Supplementary methods
Primers for quantitative polymerase chain reaction
See Supplementary Table E1.
Lentiviral and retroviral constructs
The MOZ-TIF2 cDNA and the retroviral MSCV-MOZ-
TIF2-IRES-GFP construct were kind gifts from Dr. Brian
Huntly. To perform chromatin immunoprecipitation
(ChIP), a 3XTy1 tag was added in frame at the 50 extremity
of the MOZ-TIF2 coding sequence. The mutant was gener-
ated using the Quickchange II XL Site-Directed Mutagen-
esis Kit (Agilent Technologies) by two steps of
mutagenesis. The sequences of the primers used for muta-
genesis are:
From WT to G657E:
50-cctcaataccagcgtaaggaatatggcaggtttctcatcg
50-cgatgagaaacctgccatattccttacgctggtattgagg
From G657E to Q654E/G657E:
50- ctgccatattccttacgctcgtattgaggaagaatcatta
50-taatgattcttcctcaatacgagcgtaaggaatatggcag
All third-generation lentiviral transfer vectors used in
this study have the same backbone as EF1-eGFP [26] and
were constructed by replacing the eGFP gene with the
expression cassette of interest. The MOZ-TIF2 cDNA was
cloned into PCR2.1 TOPO (Invitrogen), creating TOPO-
MOZ-TIF2. For the bicistronic MOZ-TIF2_S8GFP lentivi-
ral vector, the MOZ-TIF2 cDNA was cloned upstream of 8
repeats of the 9-nt IRES module from the Gtx 50-UTR fol-
lowed by eGFP [27]. The GFP2a_MOZ-TIF2 lentiviral vec-
tor was constructed by fusing eGFP to the foot-and-mouth
disease virus self-cleaving 2a peptide sequence (F2A) [28]
and the first 256 bp of the MOZ-TIF2 cDNA by PCR. The
resulting fragment was sequenced and used to replace the
first 256 bp of MOZ-TIF2 in TOPO-MOZ-TIF2, creating
TOPO-GFP2a-MOZ-TIF2. Subsequently the GFP2a-
MOZ-TIF2 cassette was cloned into the lentiviral back-
bone. Supplementary Figure E1 is a schematic of the
MOZ-TIF2 vectors.
Antibodies
See Supplementary Table E2.
Lentiviral and retroviral constructs, virus production
and infection of the cells
The VSVg pseudotyped lentiviral particles were produced
using a third-generation self-inactivating lentiviral vector
system. Briefly, viral supernatant was harvested from trans-
fected HEK293T cells 2, 3, and 4 days posttransfection. Su-
pernatant was passed through a 0.45-mm filter (Millipore),
concentrated by ultracentrifugation (2 hours at
20,000 rpm, 47,000K, 4C; Optima L-90K ultracentrifuge;
Beckman Coulter) and resuspended in phosphate-buffered
saline. Viral titres were expressed as HeLa cell transducing
units per milliliter (TU/mL) as determined by flow cytom-
etry for eGFP (FACS Calibur; Becton-Dickinson Biosci-
ences) 72-h posttransduction.
Retroviral particles were produced using the Plat-E
packaging cell line as described previously [29]. Briefly,
viral supernatant was harvested from transfected Plat-E
cells 2 and 3 days posttransfection. Supernatant was passed
through a 0.45-mm filter (Millipore).
Infection of c Kitþ cells with the retrovirus
Bone marrow from adult (10–14 weeks) WT mice was
flushed from the femurs. After red blood cell lysis, the
cells were stained with a biotinylated anti c-Kit antibody
(BD Biosciences, Clone 2B8m 553353) and incubated
with anti-biotin magnetic MACS beads (2 mL for 106 cells,
Miltenyi Biotec). After being washed with 10% serum in
phosphate-buffered saline, the c Kitþ cells were enriched
using an LS column and the manual MACS Separator
magnetic isolation device (Miltenyi Biotec) accordingly
to the manufacturer’s protocol. The c Kitþ cells were in-
fected using retroviral supernatants and retronectin,
following the manufacturer’s protocol (Takara, Clontech).
Briefly, 10 mg of retronectin was coated in a noncoated 48-
well plate for 2 hours at room temperature, the plate was
then blocked for 30 min with 1% phosphate-buffered sa-
line–bovine serum albumin, and the retroviral supernatant
was added to the well and centrifuged for 2 hours at
1,500g at 32C. After removal of the supernatant,
50,000 cells were added, and cells were incubated from
24 to 48 hours.
Expression analysis by PCR and qPCR
RNAs were extracted with the RNeasy kit from Qiagen.
Half a microgram of RNA was subjected to reverse tran-
scription using the high-capacity cDNA reverse transcrip-
tion kit (Thermofisher Scientific). The Universal PCR
Master Mix or the Power SYBR Green Master Mix (Ther-
mofisher Scientific) was used for the quantitative PCRs.
Serial replating assay
Forty-eight hours after infection, 10,000 cells infected with
the retrovirus coding for MOZ-TIF2 IRES GFP or for GFP
only were plated in a semisolid methylcellulose-based me-
dium containing stem cell factor, interleukin-3, granulo-
cyte–macrophage colony-stimulating factor, TPO
(obtained from the supernatant of producing cell lines, 1/
100 dilution), interleukin-11, erythropoietin, interleukin-6,
and mouse colony-stimulating factor (R&D System), in a
35-mm dish (Corning). After 7 days in culture, the colonies
were counted. The cells were then harvested and replated in
a new dish.
Cytospin and MGG staining
Fifty thousand cells were cytospun at 800 rpm for 5 min on
a microscopy slide. The cells were then stained for 3 min in
the May–Grunwald staining solution (VWR Chemicals),
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rinsed in water, and stained for 20 min in the Giemsa stain-
ing solution diluted 20 times in water (VWR Chemicals).
In vivo assay of leukemic potential of
MOZ-TIF2-expressing c Kitþ cells
Twenty-four hours after infection, 500,000 c Kitþ cells
from PEP3 mice (CD45.1) infected with the MSCV-
MOZ-TIF2-IRES-GFP retrovirus were injected into irradi-
ated C57/Bl6 recipient mice (CD45.2). All animal work
was performed under regulation in accordance with the
UK Animal Scientific Procedures Act (ASPA) 1986. Ani-
mal experiments were approved by the Animal Welfare
and Ethics Review Body (AWERB) of the Cancer Research
UK Manchester Institute.
Flow cytometry
Cell cycle analysis was performed using the Click-iT EdU
Alexa Fluor 647 Flow Cytometry Assay Kit following the
manufacturer’s protocol (Thermo fisher scientific). After
30 min of incubation with EdU, the cells were fixed and
permeabilized. Detection of EdU was performed with the
Click-It dye conjugated with AF647, and DNA content
was stained with FxViolet. Apoptosis analysis was per-
formed using the PE Annexin V Apoptosis Detection Kit
(BD Biosciences). The cells were washed and stained
with 5 mL of PE Annexin V and 7 mL of 7-AAD for
15 min at room temperature in the dark.
Western blot
Thirty micrograms of proteins were loaded in a precast gel
(Nupage, Invitrogen), and subjected to migration for 1 hour
30 min at 100 V. The proteins were transferred onto a nitro-
cellulose membrane using the iBlot device; the blocking
and antibody probing were performed using the iBind de-
vice (Invitrogen). The antibodies used are listed in
Supplementary Table E2.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation was performed using the
High Cells Chip Kit (Diagenode) following the instructions
of the manufacturer. Five million cells were fixed for 8 min
with 1% formaldehyde; after being washed with phosphate-
buffered saline, the nucleus were isolated and sonicated for
15 cycles (30 sec on/30 sec off) with the Bioruptor NGS
(Diagenode). The antibodies and quantities used for immu-
noprecipitations are listed in Supplementary Table E2. The
pull-down experiments were conducted overnight. Eluted
chromatin was quantified by quantitative PCR. Data were
expressed as enrichment over Ig control.
Statistics
The error bars in the graphs represent standard deviations.
Statistical comparisons of data sets were performed with
the two-tailed Student’s t test.
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Supplementary Figure E1. Schematic overview of the MOZ-TIF2-
expressing lentiviral vectors used in this study. Ef1 5 human elongation
factor 1a promoter; LTR 5 long terminal repeat; j 5 viral packaging
signal; rre 5 rev responsive elements; cppt 5 central polypurine tract;
PRE 5 hepatitis B virus posttranscriptional regulatory element;
GFP5 enhanced green fluorescent protein; ires5 internal ribosomal entry
site, 8 repeats of the 9-nt IRES module from the Gtx 50 UTR; 2a 5 foot-
and-mouth disease virus self-cleaving 2a peptide sequence -F2A.
Supplementary Table E1. Primers for qPCR
Universal probes from Roche Sequence
mouse p16 þ p19 81 CGACGGGCATAGCTTCAG
GCTCTGCTCTTGGGATTGG
mouse p21 16 AACATCTCAGGGCCGAAA
TGCGCTTGGAGTGATAGAAA
mouse p53 4 GCAACTATGGCTTCCACCTG
TTATTGAGGGGAGGAGAGTACG
mouse p19 106 GGGTTTTCTTGGTGAAGTTCG
TTGCCCATCATCATCACCT
mouse p16 SYBR GTACCCCGATTCAGGTGATG
CGAATCTGCACCGTAGTTGA
mouse IL6 6 GCTACCAAACTGGATATAATCAGGA
CCAGGTAGCTATGGTACTCCAGAA
mouse beta actin 106 TGACAGGATGCAGAAGAAGA
CGCTCAGGAGGAGCAATG
Primers for ChIP
mouse HOXA9 promoter SYBR GAGCGGTTCAGGTTTAATGC
TGCCTGCTGCAGTGTATCAT
mouse p16G promoter SYBR ACTCAGCTTGCTTGGTAGCAG
GTTGGCCCTGCTTCTGTC
mouse p16H promoter SYBR AATGCCAGGCCTTTAATCCT
CCTGGAACTCAGCATAAACTCA
mouse p16I promoter SYBR TTCTAATACCTGGGTGTTGCAC
AAAGTGAACTAGTCCTTCTCGAAATC




mouse TBP promoter SYBR CCGCAGTGCCCAGGTAACGG
GGGACCCGCTGCAGAAGTCG
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Supplementary Table E2. Antibodies
Application Company Clone/catalog no. Dilution/quantity
p16INK4a Western blot Sigma SAB4500072 1/2,000
b-Actin Western blot Sigma A1978 1/10,000
p53 Western blot Abcam ab78316 1/1,000
p53 k120 Ac Western blot Abcam ab26 1/1,000
Ty1 ChIP Diagenode C15200054 6 mg per IP
IgG isotype ChIP Diagenode kch-803-015 6 mg per IP
c kit biotinylated Purification of ckitþ cells BD Biosciences Clone 2B8m, 553353 1.5 mL for 10  106 cells
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